Replies to post #73324 on Biotech Values

[genisi]

Also, Pfizer Inc.'s Selzentry was approved by the FDA in August, bringing another HIV anti-viral to the market. [Selzentry is IMO a niche product.]

Merck's vicriviroc, also a CCR5 antagonist, a class that has little role in HIV treatment, failed in two phase III studies in experienced HIV patients.

http://www.reuters.com/article/idCNN2017965820100120?rpc=44